Expert Insights on COVID-19 Prophylaxis in Patients With Multiple Sclerosis and Related Disorders

1.50 CME
1.50 NCPD
90 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Expert Insights on COVID-19 Prophylaxis in Patients With Multiple Sclerosis and Related Disorders

Overview


Provider Statement

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.

Support Statement

This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Release date: September 27, 2024
Expiration date: September 27, 2025
The estimated time to complete the activity is 90 minutes.

Target Audience

Neurologists, nurse practitioners, PAs, nurses, pharmacists, and other members of the health care team caring for patients with MS.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the rationale for the use of monoclonal antibodies for COVID-19 pre-exposure prophylaxis in patients with MS
  • Review monoclonal antibodies for COVID-19 pre-exposure prophylaxis used with past FDA Emergency Use Authorization
  • Discuss ongoing trials of monoclonal antibodies being studied for pre-exposure prophylaxis of COVID-19 in immunocompromised patients
  • Identify patients with MS who may benefit from monoclonal antibodies for COVID-19 pre-exposure prophylaxis
  • Review current guidance on pre-exposure prophylaxis of COVID-19 from regulatory agencies and professional medical organizations
  • Employ team-based best practices for patient and care partner education on COVID-19 prevention, and implications on disease course and disease modification

Faculty


Program Chair


Avindra Nath, MD
National Institutes of Health
Clinical Director
National Institute of Neurological Disorders and Stroke
Bethesda, MD

Program Faculty


Jacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS
Professor, Vice Chair of Research
Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Neurology, University of Colorado, Anschutz Medical Campus
Aurora, CO

Anne H. Cross, MD, FAAN
Professor of Neurology
Manny and Rosalyn Rosenthal and Dr. John L. Trotter MS Center Chair in Neuroimmunology
Section Head of the Neuroimmunology/MS Section
Washington University School of Medicine
Saint Louis, MO

Jaime Imitola, MD, FAAN, FANA
Professor of Neurology, Vice-Chair of Research in Neurology
Chief, Division of Multiple Sclerosis and Neuroimmunology
Director, UConn Health Comprehensive MS Center
UConn School of Medicine
Farmington, CT

Carrie Sammarco, DrNP, FNP-C, MSCN
Nurse Practitioner
NYU Langone MS Comprehensive Care Center
New York, NY

Cameron R. Wolfe, MBBS (Hons), MPH, FIDSA, FAST
Professor of Medicine
Transplant Infectious Disease
Duke University Medical Center
Durham, NC

Joint Accreditation Statement

Jointly Accredited In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation

Physicians

The CMSC designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

The CMSC designates this activity for a maximum of 1.5 NCPD credits (1.5 in the area of pharmacology).

Pharmacists

This knowledge-based activity, JA4008165-9999-24-009-H01-P, qualifies for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit.

All other health care professionals completing this course will be issued a statement of participation.

How to Participate in this Activity and Obtain CE credit

There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:

There are no fees for participating in and receiving credit for this activity. During the period September 27, 2024, through September 27, 2025, participants must read the learning objectives and faculty disclosures and study the educational activity.

Upon successfully completing the posttest with a score of 80% or better and the activity evaluation, your certificate will be made immediately available to you.

Faculty and Disclosure of Conflicts of Interest


Disclosure of Financial Relationships


In accordance with ACCME’s Standards for Integrity and Independence in Continuing Education, CMSC and Catamount Medical Education require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Catamount Medical Education mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Catamount Medical Education seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Catamount Medical Education are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Faculty
Avindra Nath, MD has disclosed no relevant financial relationships.

Jacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS
Advisory Board: EMD Serono; Novartis Pharmaceuticals Corporation

Anne H. Cross, MD, FAAN
Consulting Fees: Biogen; Bristol Myers Squibb; Genentech; Janssen; Novartis Pharmaceuticals Corporation; Octave
Contracted Research: Genentech

Jaime Imitola, MD, FAAN, FANA has disclosed no relevant financial relationships.

Carrie Sammarco, DrNP, FNP-C, MSCN has disclosed no relevant financial relationships.

Cameron R. Wolfe, MBBS (Hons), MPH, FIDSA, FAST
Consulting Fees: Atea; Biogen; Janssen
Contracted Research: AstraZeneca

Planners and Independent Reviewers
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Our Policy on Privacy

The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CE activities viewed and the posttest and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information. Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For questions about this activity, please contact Catamount Medical Education at info@catmeded.com .

Course Viewing Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.